Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:ABVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$254.95+0.1%$221.27$184.63▼$261.64$450.48B0.37.18 million shs2.28 million shsABVXAbivax$144.44+0.3%$113.25$7.70▼$148.83$11.53B0.871.60 million shs741,022 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-2.34%+0.36%+11.90%+23.55%+34.44%ABVXAbivax-0.46%+49.76%+41.82%+23.62%+1,706.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$254.95+0.1%$221.27$184.63▼$261.64$450.48B0.37.18 million shs2.28 million shsABVXAbivax$144.44+0.3%$113.25$7.70▼$148.83$11.53B0.871.60 million shs741,022 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-2.34%+0.36%+11.90%+23.55%+34.44%ABVXAbivax-0.46%+49.76%+41.82%+23.62%+1,706.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$256.670.58% UpsideABVXAbivax 2.81Moderate Buy$146.001.25% UpsideCurrent Analyst Ratings BreakdownLatest ABVX and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026ABBVAbbVie HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.007/6/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $265.007/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$135.00 ➝ $155.007/1/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$187.006/30/2026ABVXAbivax HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026ABVXAbivax GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$150.00 ➝ $175.006/30/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$108.00 ➝ $158.006/30/2026ABVXAbivax Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$140.00 ➝ $148.006/30/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$90.00 ➝ $110.006/23/2026ABBVAbbVie Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.37$14.80 per share17.24($1.83) per share-139.45ABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03125.6715.920.865.79%-576.45%13.39%7/31/2026 (Estimated)ABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/14/2026 (Estimated)Latest ABVX and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2026Q2 2026ABBVAbbVie$3.79N/AN/AN/A$16.77 billionN/A5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.71%+6.80%340.89%53 YearsABVXAbivaxN/AN/AN/AN/AN/ALatest ABVX and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.733.19%7/15/20267/15/20268/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68ABVXAbivaxN/A8.258.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ABVXAbivax47.91%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%ABVXAbivaxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableABVXAbivax6179.77 millionN/ANot OptionableABVX and ABBV HeadlinesRecent News About These CompaniesAbivax: Wall Street Catches Up to the Data...1 hour ago | marketbeat.comAbivax closes $920 million public offeringJuly 7 at 7:45 AM | thepharmaletter.comTAbivax Announces Closing of $920 Million Public OfferingJuly 6 at 4:05 PM | globenewswire.comAnalysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)July 5 at 8:01 AM | theglobeandmail.comPictet Asset Management Holding SA Reduces Position in Abivax SA Sponsored ADR $ABVXJuly 4 at 4:47 AM | marketbeat.comABVX stock eyes over six-month high as investors double down on Abivax's lead drug bet – buyout chatter buildsJuly 3, 2026 | msn.comIs ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?July 3, 2026 | insidermonkey.comAbivax SA Raises $760 Million in Major U.S. ADS OfferingJuly 2, 2026 | tipranks.comAbivax raises $920M as underwriters fully exercise overallotment optionJuly 2, 2026 | msn.comTruist Financial Forecasts Strong Price Appreciation for Abivax (NASDAQ:ABVX) StockJuly 2, 2026 | marketbeat.comAbivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance SheetJuly 2, 2026 | wsj.comPromising Biotech Stocks To Follow Now - July 1stJuly 2, 2026 | americanbankingnews.comABIVAX (ENXTPA:ABVX) Stock Looks Expensive Even After Strong Trial ProgressJuly 2, 2026 | finance.yahoo.comAbivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)July 2, 2026 | markets.businessinsider.comAbivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)July 2, 2026 | globenewswire.comAbivax nears $11 billion valuation after fundraising eases M&A pressureJuly 1, 2026 | reuters.comAbivax (NASDAQ:ABVX) Earns "Market Outperform" Rating from Citizens JmpJuly 1, 2026 | marketbeat.comCorrection: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesJuly 1, 2026 | globenewswire.comAbivax announces trading resumption of its ordinary shares on Euronext ParisJuly 1, 2026 | globenewswire.comAbivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesJuly 1, 2026 | globenewswire.comABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis - SlideshowJuly 1, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Abivax: Wall Street Catches Up to the DataBy Chris Markoch | July 7, 2026ABVX and ABBV Company DescriptionsAbbVie NYSE:ABBV$254.95 +0.19 (+0.07%) As of 01:49 PM Eastern This is a fair market value price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Abivax NASDAQ:ABVX$144.44 +0.45 (+0.31%) As of 01:49 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise? Orbiting Capital: Lawmakers Buy SpaceX Ahead of Index Inclusion 3 Stocks With Solid Yields and Sustainabale Payouts Boost Dividends Once Again Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore 2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
